Quick Answer
FILANA THERAPEUTICS, INC. reported R&D Expense of $26.59 million for fiscal year 2025.
FILANA THERAPEUTICS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $26.59M | -61.8% |
| 2024 | $69.64M | -22.1% |
| 2023 | $89.42M | +31.4% |
| 2022 | $68.03M | +174.2% |
| 2021 | $24.81M | +735.7% |
| 2018 | $2.97M | -61.0% |
| 2017 | $7.62M | -17.0% |
| 2016 | $9.18M | +0.8% |
| 2015 | $9.10M | +24.6% |
| 2014 | $7.31M | +48.6% |
| 2013 | $4.92M | -35.3% |
| 2012 | $7.61M | -8.4% |
| 2011 | $8.30M | -47.3% |
| 2010 | $15.75M | -25.2% |
| 2009 | $21.06M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.96M | -77.6% | -22.7% |
| June 30, 2025 | $5.12M | -66.3% | -62.6% |
| March 31, 2025 | $13.67M | -15.8% | -22.7% |
| September 30, 2024 | $17.68M | -25.1% | +16.3% |
| June 30, 2024 | $15.20M | -39.1% | -6.4% |
| March 31, 2024 | $16.23M | -26.6% | -31.2% |
| September 30, 2023 | $23.60M | +27.4% | -5.5% |
| June 30, 2023 | $24.97M | — | +12.9% |
- FILANA THERAPEUTICS, INC. showed a decrease of -61.8% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, FILANA THERAPEUTICS, INC.’s r&d expense has grown by 26.3% (from $21.06 million to $26.59 million).
- The most recent figure is from FILANA THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: